Researchers at the Institute of General Physics at the Russian Academy of Sciences and the Moscow Institute of Physics and Technology said their advancement in biocomputing using nanoparticles is a step towards creating drug-delivering nanorobots.
Alnylam Pharmaceuticals received a Notice of Allowance from the U.S. Patents and Trademarks Office for an application granting the company new claims to RNA interference (RNAi) medicines.
Researchers successfully delivered the immunosuppressant tacrolimus in a self-assembled hydrogel, enabling localized therapy in patients receiving a tissue graft transplant of the leg, hand or face.
The FDA's Pulmonary-Allergy Drugs Advisory Committee voted 10-3 to recommend approval of Boehringer Ingelheim's mist formulation of its dry-powder inhalable treatment for chronic obstructive pulmonary disease.
Columbia University scientists showed that it is possible to control the size of the blood-brain barrier opening by varying the pressure of an ultrasound beam, a discovery that could herald major breakthroughs in the treatment of neurological diseases.
Engineers and cell biologists have long used pulsed lasers to stimulate cells for gene transfection, drug injection or the regulation of gene expression. Now, Japanese scientists uncovered a new, potentially less-expensive method of delivering drugs and manipulating genes of individual cells by pairing nanosecond laser energy with carbon nanotubes.
Arrowhead Research reported on Aug. 12 that patients in its Phase II clinical trial of the ARC-520 RNA interference candidate for hepatitis B had a "similar" knockdown to those reported in primate studies. The stock price fell at the very end of the trading day to close at $12.00 from an opening-day price of $13.00.
The contenders to develop new methods of tackling the problem of opioid addiction should receive a boost from a new study by the federal Agency for Healthcare Research & Quality, which found that the overuse of pain medications has resulted in a 5% average annual increase in adult hospital stays between 1993 and 2012.
A bioengineering professor says he has developed nanoparticles that can carry cancer-fighting insect toxins directly to tumors, sparing the rest of the body from nasty side effects, including damage to the heart, bleeding underneath the skin and unwanted clotting.
Researchers at the University of Washington have developed a medicated, electrospun fabric that could prevent HIV infections in women.
Researchers say they successfully tested in mice a molecular implant that contains gene-based mechanisms for delivering insulin based on feedback from an associated pH biosensor. By maintaining a healthy pH level between 7.35 and 7.45, the therapy, consisting of different genes and proteins, would prevent potentially fatal metabolic shock (ketoacidosis) in diabetics.
Ophthalmology company Oraya Therapeutics will collaborate with researchers from Boston's Dana-Farber Cancer Institute to study applications of its novel radiation therapy against cancer when used in conjunction with gold nanoparticles.
BioDelivery Sciences International announced today that it will add about 80 patients to its Phase III pivotal trial of Clonidine Topical Gel for the treatment of painful diabetic neuropathy.
Becton, Dickinson and Company today announced that its BD AutoShield Duo pen for the delivery of insulin and diabetes drugs is now available in retail pharmacies.
Graphene is one of the thinnest and strongest known materials and has been used in drug delivery before. But the Nobel Prize-winning material could get another lease on life with a new discovery from Monash University in Australia that could make graphene an important drug release component.
Polymer nanomaterials are crucial for many types of drug delivery applications, offering the flexibility and durability needed to engineer specific shapes and sizes for particular delivery solutions. Now, at Carnegie Mellon, researchers have developed a new technique for creating self-assembling fibers for this purpose, taking a cue from the natural fibers in living cells.
A team of MIT researchers successfully tested a thin-film drug delivery system enabling steady, sustained release of medication for about 14 months, a scientific advancement with major commercial implications.
Stentys announced that it is discontinuing enrollment of its Apposition V trial for its bare metal stent and focusing its resources and money on its next-generation sirolimus-eluting stent featuring a new delivery catheter.
Like the tiny organelles used to propel some bacteria, artificial cilia developed by German engineers could someday help deliver drugs.
Oraya Therapeutics, the developer of a low energy X-ray beam that can safely deliver radiation therapy to the into the eye, is expanding its presence in Europe. The 20-minute one-time procedure is designed to reduce the need for anti-vascular endothelial growth factor injections in patients with wet age-related macular degeneration.